Depressed sarcoplasmic reticulum (SR) Ca 2+ cycling, a universal characteristic of human and experimental heart failure, may be associated with genetic alterations in key Ca 2+ -handling proteins. In this study, we identified a novel PLN mutation (R25C) in dilated cardiomyopathy (DCM) and investigated its functional significance in cardiomyocyte Ca 2+ -handling and contractility.
Introduction
Dilated cardiomyopathy (DCM), a common cause of heart failure, is characterized by dilation and impaired contraction of the left ventricle. Multiple aetiologies may underlie DCM, including rare variants in more than 30 genes, which initiate diverse pathophysiological mechanisms leading to left-ventricular dysfunction or arrhythmia and increased morbidity and mortality. 1 A common clinical hallmark and characteristic of failing cardiomyocytes is the defective Ca 2+ homeostasis, exhibited by a prolonged decay time of intracellular Ca 2+ transient and changes in systolic and diastolic Ca 2+ levels. 2 -4 The prolonged Ca 2+ -transient decay time
and increased diastolic Ca 2+ levels may result from impaired ryanodine receptor function, decreased sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) levels, and augmented SERCA2a inhibition by phospholamban (PLN). 5 PLN is a prominent regulator of Ca 2+ cycling and a primary mediator of the b-adrenergic effects resulting in enhanced cardiac output. 6, 7 In the dephosphorylated state, PLN inhibits SERCA2a and shifts its Ca 2+ activation towards lower apparent Ca 2+ affinity. However, upon PKAmediated phosphorylation, the inhibition on SERCA2a by PLN is relieved and its Ca 2+ affinity is increased. 7 Thus, PLN plays a key role in the regulation of Ca 2+ reuptake by SERCA2a to induce relaxation and decrease diastolic Ca 2+ levels. It is also a prominent mediator of the b-adrenergic stimulatory responses in the heart. 7 The important role of PLN in cardiac function has prompted searches for human PLN genetic variants, which may be associated with DCM. Indeed, four mutations have been identified in the coding region of PLN. The first mutation was V49G, which resulted in potent inhibition of the Ca 2+ affinity of SERCA2a. Cardiac overexpression of the V49G mutant PLN in mouse led to super-inhibition of cardiac contractility and remodelling, which progressed to DCM and early mortality. 8 The second mutation identified had a stop codon for Leucine 39 (L39X-PLN) with onset of DCM and heart failure during the teenage years. 9 The third human mutation, R9C, had no effects on SERCA2a activity under basal conditions but appeared to trap PKA, which blocked PKA-mediated phosphorylation of even wild-type PLN. The detrimental effects of such chronic inhibition of SERCA2a activity resulted in DCM. 10 The fourth PLN mutation was a deletion of Arg-14 (Arg14Del). 11 It was found that heterozygous carriers exhibited inherited DCM with left-ventricular dilation, contractile dysfunction, variable conduction system disease with episodes of malignant ventricular arrhythmias in some carriers and death by middle age. 12, 13 The mechanism underlying the detrimental effects of this human mutation involves super-inhibition of SERCA2a activity, likely mediated through a disturbance in the structure of PLN. 11 These findings add to accumulating evidence that myocellular calcium dysregulation caused by mutations in human PLN is sufficiently deleterious to cause DCM and initiate heart failure.
In this study, we report a new mutation (R25C) in the coding region of the human PLN gene (PLN), identified in a pedigree with DCM that also showed prominent ventricular arrhythmia and need for implantable cardiac defibrillators (ICDs). 14, 15 Exome sequencing of affected family revealed that they had a R25C-PLN mutation, which was associated with super-inhibition of SERCA2a, depressed myocyte contractile and Ca 2+ -kinetic parameters and increased arrhythmias in cardiomyocytes.
The mechanisms underlying the detrimental effects of this mutation include enhanced interaction of R25C-PLN mutant with SERCA2a, leading to super-inhibition of SERCA2a activity and increased Cam kinase II (CaMKII) activity associated with hyper-phosphorylation of Serine 2814 in RyR.
Methods
For details regarding methods, refer to the Supplementary material online, Methods.
Identification of a PLN mutation and generation of adenoviruses
For the human study, written informed consent was obtained and methods were conducted in accordance with the Declaration of Helsinki, and the study was approved by the Institutional Review Boards of Oregon Health and Science University and the University of Miami in FL, USA. Genomic DNA was extracted using standard procedures and PLN exomes were sequenced. 15, 16 Adenoviruses expressing green fluorescent protein (Ad.GFP), WT-PLN (Ad.WT), and R25C-PLN (Ad.R25C) were generated. 9 
Myocyte culture and quantitative immunoblotting
Animals were handled according to the Institutional Animal Care and Use Committee at the University of Cincinnati. Myocytes from adult male rats were isolated, 17 cultured for 2 h and infected with adenoviruses. At 24 h post-infection, we determined PLN levels by western blots and initial rates of SR Ca 2+ uptake. 18 Data were analysed by non-linear regression using the OriginLab 5.1 program.
Cardiomyocyte contractility and Ca 21 transients
Contractions were obtained at 0. 
Aftercontractions in rat cardiomyocytes
Rat ventricular myocytes were paced at 2 Hz in the presence of 1 mmol/L ISO. After 2 or 3 trains of stimulation, pacing was stopped and spontaneous aftercontractions within 2 -5 s were recorded.
CaMKII activity assay
Cell lysates from infected myocytes were processed for CaMKII activity (Cyclex Kit, MBL International, Woburn, MA, USA).
Statistics
Results are expressed as mean + SEM. Comparisons were evaluated by one-way ANOVA and a post-hoc Tukey test. Fisher's exact test was used for calcium sparks, waves, and after contractions. Values of P , 0.05 were considered significant.
Results

Identification of a novel PLN mutation in a familial DCM pedigree
Forty-eight variants, meeting our established criteria for exome sequencing analysis, 15 were identified in two sisters (III.1 and III.3) in our family pedigree ( Figure 1 ). Of these 48, three were in previously identified DCM genes, including a novel heterozygous PLN mutation that resulted in change of arginine into cysteine at position 25, and two missense mutations in Titin (TTN) (A3656S and P7178S). Because it is known that even rare (,0.5%) TTN missense mutations are prevalent in control samples, 16, 21 these missense variants were considered unlikely to be the cause of DCM. The PLN mutation had high conservation scores (Phastcons 1; GERP 4.31), and based on other heterozygous PLN missense mutations causing DCM, 8 -11 it was hypothesized that this mutation also may alter PLN activity. None of the genes harbouring the remaining 45 variants were associated with known cardiovascular disorders. No additional PLN variants were identified in 16 other families.
15
A pedigree with the PLN mutation status is shown in Figure 1 . Sanger sequencing confirmed that the PLN mutation was present in the sisters (III.1 and III.3), the proband (III.2) who also carried a previously identified LMNA mutation, 15 as well as in his mother (II.3), who had DCM but was not found to carry the LMNA mutation. 15 
Clinical characteristics
Clinical characteristics of family members with the PLN mutation are provided ( Table 1) . The proband (III.2) presented at age 47 with sudden cardiac arrest and was diagnosed with non-ischaemic DCM upon resuscitation. An ICD was placed from which he has received multiple appropriate shocks. Approximately 10 years later, he required heart transplantation due to worsening heart failure. Two of his sisters were also found to harbour the R25C-PLN mutation. His older sister (III.1) was first screened clinically at age 51 and was found to have leftventricular enlargement but preserved systolic function. Despite already receiving an angiotensin receptor blocker (ARB), 2 years later her ventricular function had deteriorated. Non-sustained ventricular tachycardia (NSVT) was found on Holter monitoring, and an ICD was placed prior to the onset of any heart failure. She was treated with fulldose beta blockade and an ARB. Over the course of the following 10 years, two cardioversions were required due to persistent atrial fibrillation. The proband's younger sister (III.3), who also had NSVT and required an ICD, was diagnosed with DCM at age 45 after presenting with signs of heart failure. Their mother (II.3), who had complained of palpitations since age 47, had premature ventricular contractions at age 57. She was diagnosed with DCM at 71 and had multiple PVCs, couplets, and NSVT for years, for which an ICD was placed at age 84 because of progressive pump dysfunction. She progressed to chronic atrial fibrillation and received multiple cardioversions, and died from heart failure at age 90.
Expression of mutant PLN in adult cardiomyocytes and Ca 21 uptake assay
To determine whether the inhibitory effects of PLN on cardiac contractility are modified by the R25C mutation, recombinant adenoviruses encoding GFP, WT-PLN, or R25C-PLN were transduced into adult rat ventricular myocytes. The protein levels of PLN in infected cardiomyocytes were assessed by SDS -PAGE and western blots. Quantitative immunoblotting of cell lysates revealed a similar ratio of PLN pentamers to monomers in mutant PLN (85.8%) cardiomyocytes, compared with WT-PLN (86.6%) and GFP (84.9%) groups ( Figure 2A ). Furthermore, upon boiling the cardiac homogenates prior to SDS -PAGE, the mutant could be dissociated into monomers, similar to WT-PLN. There were no significant changes in the SERCA2a protein levels in the infected mutant cardiomyocytes (Figure 2A ). When the apparent PLN/SERCA2a ratio was calculated, it was found to be a 1.9-fold in R25C myocytes, compared with the GFP group, and this ratio was similar to that for WT-PLN (1.93) ( Figure 2B ).
To examine the functional significance of the R25C substitution in PLN and its impact on SERCA2a regulation, the initial rates of ATPdependent, oxalate-facilitated SR Ca 2+ uptake were measured in cell lysates from infected cardiomyocytes. There were no significant differences in the maximal rates of SR Ca 2+ uptake between GFP, WT, or R25C groups. However, the EC50 value for Ca 2+ dependence of Ca 2+ uptake was significantly higher in WT-PLN cells (0.40 + 0.03 mM), compared with the GFP group (0.22 + 0.02 mM), consistent with our previous findings. 22 Interestingly, R25C-PLN further increased the SERCA2a EC50 value to 0.63 + 0.07 mM ( Figure 2C) , Thus, the mutant PLN is a super-inhibitor of the affinity of SERCA2a for Ca 2+ compared with WT-PLN.
Functional analysis of the R25C-PLN mutant
Overexpression of WT-PLN has been shown to lead to significant depression of cardiomyocyte function. 22 To determine whether the superinhibitory effects of the R25C mutation on SERCA2a activity translated into alterations at the cellular level, the contractile parameters of infected cardiomyocytes were assessed. The resting cell length in mutant PLN infected myocytes was not altered compared with the WT-PLN or GFP groups. However, the amplitude of basal cell contraction (fractional shortening, FS%) was more depressed in myocytes overexpressing R25C mutant PLN (60%) than in myocytes overexpressing WT-PLN (76%), compared with GFP control (100%) ( Figure 3A and B). The maximal velocities of cardiomyocyte shortening and re-lengthening were also more depressed in myocytes with mutant PLN (+dL/dt: 52%; 2dL/dt: 46%) than in cells with WT-PLN (+dL/dt: 67%; 2dL/dt: 66%), compared with GFP controls (100%) ( Figure 3C and D).
3. Figure 4A and B). The time to 50% decay of the Ca 2+ signal was prolonged by 65% in cardiomyocytes overexpressing mutant and by 32% in cardiomyocytes overexpressing WT-PLN, relative to GFP group ( Figure 4C ). In addition, intracellular diastolic Ca 2+ was also analysed and it was found to be increased by 18% in R25C-PLN compared with WT-PLN or GFP cardiomyocytes ( Figure 4D) . Thus, the R25C-PLN mutant depressed mechanical and Ca 2+ kinetic parameters and increased diastolic Ca 2+ levels, consistent with the enhanced inhibition of SERCA2a. Figure 4E and F) , indicating a super-inhibitory effect of mutant-PLN on SR Ca 2+ content. However, the time constant for 50% decay of the caffeine-induced Ca 2+ transient (T 50 ), which mainly reflects Ca 2+ extrusion by the sodium/calcium exchanger (NCX), was similar between the three groups ( Figure 4G ).
Isoproterenol stimulation relieves the inhibitory effects of R25C-PLN
Phospholamban has been postulated to be phosphorylated during b-adrenergic stimulation, resulting in relief of its inhibitory effects on SERCA2a and cardiac function. 7 To determine whether the super- Figure S1 ).
3.7
The mutant R25C-PLN exhibits enhanced association to SERCA2 and PKA abrogates this effect
To gain insights into the mechanisms associated with increased inhibition of SERCA2a by R25C-PLN, we co-expressed SERCA2 with either WT or mutant PLN in HEK cells to evaluate their interactions in the absence of endogenous proteins. For this, we generated a GFP-WT-PLN or GFP-R25C-PLN constructs and transiently co-transfected these along with SERCA2 in HEK 293 cells. Initial immunofluorescence studies indicated that, similar to GFP-WT-PLN, the GFP-R25C-PLN mutant exhibited co-localization with SERCA2 in ER ( Figure 5A ). Subsequent immunoprecipitation studies from co-transfected cells revealed a significant increase in the levels of SERCA2 in the R25C-PLN sample, compared with WT-PLN ( Figure 5B and C ) , indicating enhanced formation of the SERCA2/R25C-PLN protein complex. Interestingly, parallel experiments in cell lysates, that had been previously phosphorylated by PKA, revealed that phosphorylation of R25C-PLN abolishes the increased interaction of this mutant with SERCA2, as similar levels of SERCA2 were observed in the phosphorylated R25C-PLN and WT-PLN protein complexes ( Figure 5D and E). These findings are consistent with relief of the mutant PLN super-inhibitory effects on contractility and Ca 2+ -cycling upon Iso-stimulation of cardiomyocytes (see Supplementary material online, Figure S1 ).
Increased Ca 21 sparks, waves, diastolic SR Ca 21 leak, and stress-induced aftercontractions in R25C-PLN cardiomyocytes
As described earlier, all R25C affected members in the family pedigree developed cardiac arrhythmias ( Figure 1 and Table 1 ). The molecular trigger for arrhythmia is enhanced SR Ca 2+ leak, evidenced by increases in Ca 2+ sparks or waves at the cardiomyocyte level. 23 To determine the effect of R25C on SR Ca 2+ release, we examined Ca 2+ spark properties in intact quiescent cells. The line-scan and three-dimensional images for Ca 2+ sparks are presented in Figure 6A . It was observed that spark frequency was two-fold in the mutant PLN cardiomyocytes, compared with WT-PLN or GFP cardiomyocytes ( Figure 6B) . Next, the frequency of spontaneous Ca 2+ waves was examined in GFP, WT-PLN, and R25C-PLN myocytes. It was found that Ca 2+ waves were developed in 40% of R25C cardiomyocytes, compared with 4% of WT-PLN cells and 6% of GFP cells ( Figure 6C and D) . leak was also measured using the tertacaine protocol 25 ( Figure 6E and F ). The ratio of SR Ca 2+ leak to SR Ca 2+ load was significantly larger in R25C cardiomyocytes, compared with GFP and WT cardiomyocytes ( Figure 6G ), suggesting that R25C-PLN increases the SR Ca 2+ leak.
Next, we determined the role of R25C-PLN under stress conditions by measuring the frequency of aftercontractions in GFP, WT-PLN, and R25C cardiomyocytes at 2-Hz field stimulation in the presence of 1 mM Isoproterenol. Spontaneous aftercontractions occurred in 74% of R25C cells within 5 s after pacing was stopped, compared with 17% of WT-PLN and 16% of GFP cells ( Figure 6H and I ) . Taken together, these findings suggest that overexpression of R25C-PLN enhances the propensity for spontaneous Ca 2+ release from the SR, resulting in increased susceptibility to arrhythmia. ( Figure 7A-C) . This prompted us to determine the activity of CaMKII in cell lysates from GFP, WT-PLN, and R25C cardiomyocytes, using a non-radiographic CaMKII ELISA. We found that the activity of CaMKII in R25C myocytes was increased to two-fold compared with WT-PLN or GFP groups ( Figure 7D) , consistent with the increase in diastolic Ca 2+ in these cells ( Figure 4D ). To further confirm this finding, phosphorylation of CaMKII at Thr286 residue, which represents permanent activation of the CaMKII enzyme, was determined in cell lysates from GFP, WT-PLN, and R25C cardiomyocytes using western blots. It was observed that the level of phosphorylation of CaMKII at Thr286 was considerably higher in R25C cells, compared with the WT-PLN or GFP groups ( Figure 7E and F ) . Interestingly, the increased CaM kinase activity did not reflect altered phosphorylation of PLN (see Supplementary material online, Figure S2 ) in the mutant cells, suggesting that mutant PLN either altered CaMKII binding or increased PLN-phosphatase activity. To further examine the contribution of CaMKII mediated phosphorylation of RyR2 in the R25C-induced increases of Ca 2+ sparks and waves, KN93, the selective inhibitor of CaMKII was utilized in parallel studies with KN92 as a control. We found that KN93 completely abrogated the increased Ca 2+ spark frequency ( Figure 7G ), indicating that the aberrant SR Ca 2+ release was contributed by the increased CaMKII phosphorylation of RyR. Furthermore, KN93 fully abolished the Ca 2+ waves, elicited by R25C-PLN ( Figure 7H ).
These data suggest that the aberrant SR Ca 2+ leak and resultant Human R25C-PLN causes arrhythmias arrhythmia were associated with increased CaMKII activity and hyper-phosphorylation of RyR at Ser2814.
Discussion
In the current study, we identified a novel R25C-PLN mutation in familial DCM, which acts as a super DCM-elicited arrhythmias and those resulting from a specific molecular defect remains challenging, although the exception has been the category of 'DCM with prominent arrhythmia', 28 assigned predominantly to variants in LMNA, but also observed with variants in SCN5A 29 or
DES. 30 Our current work augments this established gene/phenotype paradigm, as previously reported rare variants in PLN have been associated with predominantly monophenotypic DCM, while the R25C PLN variant leads to promiment arrhythmias, which we suggest may be due in part to novel, specific mechanisms. These PLN-mutation carriers presented with arrhythmia in middle-age and in the setting of DCM, characterized by an 'adult-onset', as commonly observed in most of genetic cardiomyopathy. Another recent report with the R14del-PLN variant, a founder mutation in a large number of Dutch individuals, also suggested a propensity to arrhythmia, although a key predictor of arrhythmia was reduced systolic function (,45%). 13 Previous studies regarding the role of super-inhibitor PLN mutants in mouse models suggested that the depressed SERCA2 activity and contractility were associated with hypertrophic remodelling and ventricular failure over the long term. 31, 32 Similar to those studies, our functional data further support the role of PLN mutations in DCM.
The mechanisms underlying the super-inhibitory activity of R25C-PLN appear to include increased association or interaction of this mutant with SERCA2a, resulting in increased inhibition of SR Ca 2+ -transport.
Indeed, depressed SR Ca 2+ cycling is a major characteristic of human and experimental heart failure. Accordingly, cardiac overexpression 33 or gene transfer 34 of SERCA2a in rat models of heart failure not only significantly improved cardiac contractile function, but increased survival and cardiac metabolism. Similarly, inhibition of PLN activity resulted in enhanced SR Ca 2+ cycling and cardiac contractility 34, 35 as well as attenuated heart-failure progression. 36 In addition, RyR inhibition by calstabin improved cardiac function in failing hearts. 23 These studies suggest that disturbed SR Ca 2+ cycling may serve as a root cause of heart failure and this hypothesis has been well supported by recent studies in human patients. 37, 38 Interestingly, the R25C-PLN was also associated with increased Ca 2+ sparks, waves, and stress-induced after-contractions, which may have contributed to the clinical features of cardiac arrhythmia in R25C carriers at the cellular level. The underlying pathways appear to involve increased inhibition of SERCA2a by mutant PLN, resulting in elevated diastolic Ca 2+ and activation of CaMKII 39 ( Figure 4D) . Actually, several studies in neuron cells and cardiomyocytes have shown that sustained intracellular Ca 2+ elevation enhances CaMKII auto-phosphorylation and increases Ca 2+ /calmodulin-independent kinase activity. 40 -42 The activation of CaMKII reflected enhanced phosphorylation of RyR2 at Ser2814, leading to increases in SR Ca 2+ leak and arrhythmia, consistent with previous studies. 42 -44 Indeed, inhibition of CaMKII activity by KN93 abrogated the increases in Ca 2+ -sparks and Ca 2+ -waves, elicited by R25C-PLN. Notably, overexpression of WT-PLN in cardiomyocytes, which resulted in a smaller degree of SERCA2a inhibition than R25C-PLN, did not significantly alter diastolic Ca 2+ levels, CaMKII activity or phosphorylation of RyR2 at Ser2814. These findings indicate that inhibition of SERCA2a beyond a threshold point has detrimental effects through increased diastolic Ca 2+ levels and CaMKII activation.
The mechanisms associated with the super-inhibitory effects of R25C-PLN are likely mediated through a disturbed conformational structure of PLN. Arg25 is highly conserved across species and this residue supplies a positive charge, which is important for maintaining the hinge region of PLN in the hydrophilic cytosolic environment. Thus, the Arg25 replacement with cysteine, a non-polar amino acid, could destabilize the hinge angle, leading to conformational changes that enhance the association between PLN and SERCA2a. 45 Interestingly, the super-inhibitory effects of mutant PLN were completely relieved upon isoproterenol stimulation, which also reduced the binding of R25C-PLN with SERCA2 to similar levels as WT-PLN, indicating that this mutation did not alter the ability of PLN to get phosphorylated. Future studies on the three-dimensional structure of mutant PLB and SERCA2a will provide insights into the mechanisms by which R25C-PLN exerts its inhibitory effects and may contribute to design of appropriate molecules to relieve PLB inhibition on SERCA2a and improve function in DCM carriers. In summary, the current study demonstrates that a newly identified human R25C-PLN mutant is associated with DCM and increased propensity to arrhythmias. Our findings support the view that suppression of Ca 2+ -resequestration by the SR may result in depressed contractility as well as activation of other detrimental pathways, which further exacerbate impaired Ca 2+ -handling, resulting in arrhythmias and deteriorative remodelling. Thus, the mutation reported in this study, together with the previously reported human PLN mutations, point to the paramount importance of genetic and cardiac screening for these rare exome variants that disrupt normal homeostatic mechanisms for calcium cycling in the human heart.
Limitations
Other factors, including environmental or other genetic perturbations, may have also contributed to the R25C-PLN human phenotype. However, the clinical, pedigree, and functional data are compelling and congruent with prior reports of PLN mutations causing DCM.
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